Browse the evidence

Modifying the glycemic index of a high-quality dietary pattern (like DASH) does not improve cardiovascular risk factors or insulin sensitivity compared to a high-GI version of the same pattern.

Do not assume that choosing 'low GI' versions of healthy foods (like low-GI pasta or bread) offers extra cardiovascular benefits over standard versions if the overall diet is already healthy. Focus on the quality of the entire diet (e.g., DASH or Mediterranean patterns) rather than optimizing for glycemic index.

Metabolic bariatric surgery (MBS) is the most effective intervention for achieving long-term and sustained weight loss and can reverse certain metabolic defects like insulin resistance by altering gut hormone secretion.

For severe obesity, lifestyle changes alone are often insufficient. Metabolic bariatric surgery (like gastric bypass) is currently the most effective treatment for long-term weight loss and can reverse metabolic issues like diabetes by changing gut hormones.

Post-hoc exclusion of participants based on 'Unaccounted Energy' (a post-randomization variable) in feeding studies introduces severe confounding bias, artificially attenuating the observed increase in Total Energy Expenditure (TEE) associated with low-carbohydrate diets.

When evaluating low-carb diet studies, be skeptical of analyses that exclude participants who didn't 'adhere' perfectly. These exclusions often rely on flawed metrics (like Unaccounted Energy) that introduce bias. The original findings of increased energy expenditure on low-carb diets remain robust even when accounting for these methodological errors.

Obesity is a chronic, progressive, relapsing, multifactorial neurobehavioral disease driven by complex brain-gut-adipose interactions, not merely a lack of willpower.

Stop blaming yourself for your weight. Obesity is a biological disease involving hormones and brain signaling, not a character flaw. Seek medical care that treats the underlying biology, not just willpower.

Obesity is associated with increased risk of various cancers (breast, colorectal, endometrial, etc.) through mechanisms involving chronic inflammation, insulin resistance, and hormonal changes.

Maintaining a healthy weight reduces your risk of several cancers. Focus on sustainable lifestyle changes to lower your risk.

Obesity is a complex chronic disease requiring multidisciplinary care, and stigma contributes to morbidity and mortality.

Understand that obesity is a chronic disease, not a personal failure. Seek care from a multidisciplinary team that treats you with respect and empathy, as stigma can worsen health outcomes.

GLP-1 receptor agonists significantly increase the volume of retained gastric contents in fasting patients, but this does not translate to a statistically significant increase in actual pulmonary aspiration rates.

If you take a GLP-1 drug (like Ozempic or Wegovy) and have surgery, your stomach might stay fuller longer, but you are not significantly more likely to vomit into your lungs than someone who doesn't take it. Do not stop your medication without asking your surgeon or anesthesiologist, as modern guidelines suggest continuing it for most people while using other safety checks like ultrasound.

Endogenous GIP acts as an incretin that potentiates glucose-stimulated insulin secretion, and its inhibition via GIP receptor antagonists reveals this physiological role.

GIP naturally helps your body release insulin after eating. Early treatments tried adding more GIP, but it didn't work well in diabetics. New research shows that blocking GIP's natural signal helps scientists understand its true role, which is still to boost insulin, even in diabetes.

Tirzepatide is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) compared to placebo, insulin, and GLP-1 RAs, particularly at higher doses.

Expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but often improve over time. Discuss management strategies with your doctor.

Healthier food-based diet patterns cost significantly more than less healthy options, with an average increase of $1.48 per day and $1.54 per 2000 kcal.

If you are trying to eat healthier, expect to pay more. This meta-analysis confirms that healthier food-based diets cost about $1.50 more per day than less healthy ones. This is a significant financial barrier, especially for low-income populations. To mitigate this, focus on affordable healthy staples like grains and dairy, which showed smaller or no price differences, and consider policy-level changes or subsidies to make healthy food more accessible.

Healthier meats and protein options cost significantly more per serving and per calorie than less healthy options.

If you are trying to eat healthier, expect to pay more for meat. This meta-analysis confirms that healthier meat options cost about $0.29 more per serving and $0.47 per 200 kcal than less healthy options. This is the largest price difference among food groups. To mitigate this, focus on affordable healthy staples like grains and dairy, which showed smaller or no price differences, and consider policy-level changes or subsidies to make healthy food more accessible.

Global intakes of specific food groups vary widely by region and country, with some regions having very high intake of certain foods (e.g., vegetables in Sub-Saharan Africa) and very low intake of others (e.g., fruits).

Dietary recommendations should be tailored to regional food availability and cultural preferences. For example, in regions where vegetable intake is high but fruit intake is low, efforts might focus on increasing fruit consumption. Conversely, in regions with low intake of all healthful foods, a broader increase is needed.

Genetic variants in PCSK9 that lower LDL cholesterol are associated with an increased risk of type 2 diabetes, higher fasting glucose, increased bodyweight, and higher waist-to-hip ratio.

If you are considering PCSK9 inhibitor therapy (like evolocumab or alirocumab) to lower cholesterol, be aware that genetic studies suggest it may slightly increase your risk of developing type 2 diabetes and increase body weight. However, this risk is generally considered acceptable compared to the significant protection against heart attacks and strokes these drugs provide. Regular monitoring of blood sugar is recommended.

Fructose increases uric acid levels through ATP depletion and purine synthesis, a mechanism not shared by glucose or other simple sugars.

Understanding that fructose is metabolically distinct from glucose helps explain why sugary drinks and fruit juices are specific triggers for gout, even if total sugar intake isn't extremely high.

Lean mass is an inaccurate proxy for muscle mass in GLP-1 trials because it includes organs, bone, and fluids; MRI-based muscle volume z-scores provide a more accurate assessment of muscle health.

Do not rely solely on 'lean mass' numbers from standard scales or DXA scans to judge your muscle health. These numbers include water and organ weight. For a true picture of muscle, look at muscle volume and quality via advanced imaging like MRI, which shows if muscle fat is decreasing.

Higher fasting insulin levels and lower Sex Hormone-Binding Globulin (SHBG) levels causally increase the risk of PCOS, acting as key metabolic drivers of the syndrome.

Managing insulin resistance is crucial for PCOS prevention and management. High insulin and low SHBG are causal factors. Lifestyle interventions that improve insulin sensitivity (diet, exercise) can mitigate PCOS risk by addressing these metabolic drivers.

GLP-1 receptor ligands reduce cardiovascular mortality and major adverse cardiovascular events in patients with type 2 diabetes, with efficacy varying by specific drug half-life and homology to native GLP-1.

If you have type 2 diabetes and cardiovascular risk, GLP-1 receptor ligands like semaglutide or liraglutide can significantly reduce your risk of heart-related death and events. However, not all GLP-1 drugs offer this specific heart protection; shorter-acting versions may not provide the same benefit. Consult your doctor to ensure you are prescribed a GLP-1 agent with proven cardiovascular outcomes.

Obesity is a neurobiological disorder driven by genetic and environmental interactions that dysregulate brain-controlled energy homeostasis, rather than a failure of individual willpower.

Understand that obesity is a complex biological condition influenced by genetics and environment, not a simple failure of willpower. This perspective shifts the focus from self-blame to seeking effective, biologically-targeted treatments and lifestyle adjustments that work with your body's natural regulatory systems.

Obesity is a complex, chronic, multifactorial disease driven by genetic, epigenetic, psychosocial, and microenvironmental factors, rather than solely an energy imbalance.

Stop viewing obesity as a simple failure of willpower or calorie counting. Recognize it as a complex biological disease involving genetics, gut health, and stress. This shifts the focus from self-blame to seeking comprehensive medical and lifestyle interventions that address these underlying drivers.

Increased economic development and industrialization are associated with higher obesity rates primarily due to increased caloric intake and diet quality (specifically ultraprocessed foods), rather than reduced physical activity or energy expenditure.

Stop blaming your lack of exercise for your weight gain. This research shows that moving less doesn't necessarily mean you burn significantly less energy than a highly active person of the same size. The real driver of obesity in modern societies is what you eat, specifically the high proportion of ultraprocessed foods that disrupt satiety and increase absorption. Focus on reducing ultraprocessed food intake rather than obsessing over increasing physical activity expenditure to fix obesity.

Lifestyle treatment alone has modest or little long-term effect on weight loss, particularly in adults, and is often insufficient for sustainable weight maintenance due to biological drivers like hunger.

Do not blame yourself if lifestyle changes alone haven't led to lasting weight loss. The paper confirms that lifestyle treatment often has modest long-term effects due to biological factors like hunger. This is a common challenge, not a personal failure.

Dietary self-report instruments (FFQs and 24-hour recalls) significantly underestimate absolute energy and protein intake, with under-reporting rates of approximately 28% for FFQs and 15% for single 24-hour recalls, while over-reporting protein density.

Do not trust the absolute calorie or protein numbers from food diaries or apps. They consistently underestimate intake by 15-30%. If you need to know your true intake, use biomarkers (like doubly labeled water) or apply statistical calibration equations that account for your BMI, age, and sex.

Timing protein intake around resistance training sessions provides no additional benefit for muscle strength or hypertrophy compared to consuming the same total daily protein amount at other times.

Stop stressing about eating protein immediately before or after your workout. The research shows that as long as you consume enough protein throughout the day (at least 1.6 g/kg/day is suggested for maximizing muscle accretion), the specific timing of those meals does not significantly impact your muscle growth or strength gains. Focus on hitting your total daily protein goal rather than adhering to a rigid post-workout feeding window.

The cost-saving benefits of intensive lifestyle intervention are not evident in patients with a pre-existing history of cardiovascular disease, who may actually incur higher outpatient costs.

If you have type 2 diabetes and a history of heart disease, a lifestyle intervention might not save you money on healthcare bills in the long run, as outpatient costs may increase. However, it still reduces hospital stays. The primary benefit for this group may be health improvement rather than economic savings.